Review

anti psmb10 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech anti psmb10
Anti Psmb10, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti psmb10/product/Proteintech
Average 93 stars, based on 5 article reviews

anti psmb10 - by Bioz Stars, 2026-03

93/100 stars

Images

Image Search Results

$The specific increased expression of PSMB10 in post-chemotherapy nonsenescent LSCs predicts a poor AML prognosis. A Single-cell RNA-seq data ( GSE116256 ) showing postchemotherapy LSC clusters defined by senescence-associated genes. B Volcano plot showing differentially expressed genes of the defined cell population. C The overlapping upregulated genes between pretherapy LSCs and post-therapy nonsenescent LSCs. D PSMB10 mRNA expression in defined cell populations. E Kaplan‒Meier plots of the overall survival of AML patients in TCGA. F PSMB10 mRNA levels in BM CD34 + cells from healthy donors ( n = 10) and primary AML patients ( n = 21) were determined via RT-qPCR. G Relative PSMB10 protein levels in BM CD34 + subsets from healthy individuals ( n = 10), primary AML patients ( n = 17), AML patients with complete remission ( n = 15), and relapsed/refractory patients ( n = 11) analyzed via FCM. H PSMB10 mRNA levels in normal CD34 + cells, AML CD34 + cells, and AML CD34 − cells from GSE30029 . I PSMB10 mRNA levels in AML LSCs with different prognoses (left 1st), therapeutic responses (left 2nd), and therapeutic periods (right three) from single-cell RNA-seq data ( GSE185991 ). LSCs: leukemia stem cells; HSCs: hematopoietic stem cells; CR: Complete Remission; NR: No Response. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (t test). The error bars denote the means ± SDs$

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: PSMB10 maintains the stemness of chemotherapeutic drug-resistant leukemia cells by inhibiting senescence and cytotoxic T lymphocyte-mediated killing in a ubiquitinated degradation manner

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: The specific increased expression of PSMB10 in post-chemotherapy nonsenescent LSCs predicts a poor AML prognosis. A Single-cell RNA-seq data ( GSE116256 ) showing postchemotherapy LSC clusters defined by senescence-associated genes. B Volcano plot showing differentially expressed genes of the defined cell population. C The overlapping upregulated genes between pretherapy LSCs and post-therapy nonsenescent LSCs. D PSMB10 mRNA expression in defined cell populations. E Kaplan‒Meier plots of the overall survival of AML patients in TCGA. F PSMB10 mRNA levels in BM CD34 + cells from healthy donors ( n = 10) and primary AML patients ( n = 21) were determined via RT-qPCR. G Relative PSMB10 protein levels in BM CD34 + subsets from healthy individuals ( n = 10), primary AML patients ( n = 17), AML patients with complete remission ( n = 15), and relapsed/refractory patients ( n = 11) analyzed via FCM. H PSMB10 mRNA levels in normal CD34 + cells, AML CD34 + cells, and AML CD34 − cells from GSE30029 . I PSMB10 mRNA levels in AML LSCs with different prognoses (left 1st), therapeutic responses (left 2nd), and therapeutic periods (right three) from single-cell RNA-seq data ( GSE185991 ). LSCs: leukemia stem cells; HSCs: hematopoietic stem cells; CR: Complete Remission; NR: No Response. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (t test). The error bars denote the means ± SDs

Article Snippet: The supernatants of the protein lysates were incubated with the following indicated antibodies at 4 °C for 1 h: anti-PSMB10 antibody (sc-133236, Santa Cruz, mouse), anti-RPL6 antibody (A303-587A-T, Thermo Fisher Scientific, rabbit), anti-RPS6 antibody (sc-74459, Santa Cruz, mouse), anti-MDM2 antibody (sc-965, Santa Cruz, mouse), anti-P21 antibody (2947, Cell Signaling Technology, rabbit), anti-MHC-I antibody (sc-32235, Santa Cruz, mouse), and anti-SLC22A16 antibody (sc-390056, Santa Cruz, mouse).

Techniques: Expressing, RNA Sequencing, Quantitative RT-PCR

Downregulation of PSMB10 restarts senescence and promotes CTL-mediated killing of AML cells in vitro. A-D Representative images of SA-β-Gal staining (left) and the number of SA-β-Gal + cells (right) ( A ), cell cycle distribution ( B ), PSMB10 and SASP mRNA expression ( C ), and growth curves ( D ) of THP-1 and KG-1a cells after transduction with the indicated lentiviruses. Scale bar, 50 μm. E–F Statistical histogram of SA-β-gal ( E ) and EdU + percentage ( F ) for AML patient-derived BM CD34 + cells (FAB: M0/M1/M2, n = 5) or BM mononuclear cells (FAB: M5, n = 5) after PSMB10 downregulation with the indicated siRNA. G Scheme for a co-culture system of T cells and AML cells. Created with figdraw.com. H-I Percentage of Annexin V + apoptotic THP-1 ( H ) and KG-1a ( I ) cells after coculture with activated CD3 + T cells. SA-β-Gal: senescence-associated β-galactosidase; WT: wild-type; siNC: small interfering RNA negative control; MFI: mean fluorescence intensity. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (t test). The error bars denote the means ± SDs

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: Downregulation of PSMB10 restarts senescence and promotes CTL-mediated killing of AML cells in vitro. A-D Representative images of SA-β-Gal staining (left) and the number of SA-β-Gal + cells (right) ( A ), cell cycle distribution ( B ), PSMB10 and SASP mRNA expression ( C ), and growth curves ( D ) of THP-1 and KG-1a cells after transduction with the indicated lentiviruses. Scale bar, 50 μm. E–F Statistical histogram of SA-β-gal ( E ) and EdU + percentage ( F ) for AML patient-derived BM CD34 + cells (FAB: M0/M1/M2, n = 5) or BM mononuclear cells (FAB: M5, n = 5) after PSMB10 downregulation with the indicated siRNA. G Scheme for a co-culture system of T cells and AML cells. Created with figdraw.com. H-I Percentage of Annexin V + apoptotic THP-1 ( H ) and KG-1a ( I ) cells after coculture with activated CD3 + T cells. SA-β-Gal: senescence-associated β-galactosidase; WT: wild-type; siNC: small interfering RNA negative control; MFI: mean fluorescence intensity. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (t test). The error bars denote the means ± SDs

Techniques: In Vitro, Staining, Expressing, Transduction, Derivative Assay, Co-Culture Assay, Small Interfering RNA, Negative Control, Fluorescence

Downregulating PSMB10 synergistically promotes LSC eradication in conjunction with T cells in vivo. A Experimental Scheme for NCG mice transplantation. Created with figdraw.com. B Kaplan‒Meier survival plot of the 1st recipient NCG mice transplanted with shCTRL or shPSMB10 THP-1 cells or T cells (E: T = 1:2) ( n = 8). C Percentages of human CD45 + leukemia cells in the PB at indicated times ( n = 5–6). D Percentages of human CD45 + leukemia cells in the BM after the death of the 1st transplantation NCG mice at 5 weeks ( n = 7). E Spleen size and percentage of hCD45 + leukemia cells in the spleen of the 1st transplantation recipient NCG mice at 5 weeks ( n = 7). F Kaplan‒Meier survival plot of the 2nd transplantation recipient NCG mice (E: T = 1:2, n = 8). G Percentage of human CD45 + leukemia cells in the PB and BM after the death of the 2nd transplantation recipient NCG mice at 5 weeks ( n = 5). H Spleen size and percentage of human CD45 + leukemia cells in the spleen of the 2nd transplantation recipient NCG mice after the death at 5 weeks ( n = 5). I Limiting dilution assays. The table (left) shows different numbers and treatment methods of transplanted leukemic cells with or without T cells and death numbers for each 2nd transplantation recipient NCG mouse. The table (middle) shows the LSC frequency in each transplantation recipient NCG mouse group. Limiting dilution assays of the 2nd transplantation showing the frequency of LSCs (right). BM: bone marrow; PB: peripheral blood; GFP: green fluorescent protein. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (t test). The error bars denote the means ± SDs

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: Downregulating PSMB10 synergistically promotes LSC eradication in conjunction with T cells in vivo. A Experimental Scheme for NCG mice transplantation. Created with figdraw.com. B Kaplan‒Meier survival plot of the 1st recipient NCG mice transplanted with shCTRL or shPSMB10 THP-1 cells or T cells (E: T = 1:2) ( n = 8). C Percentages of human CD45 + leukemia cells in the PB at indicated times ( n = 5–6). D Percentages of human CD45 + leukemia cells in the BM after the death of the 1st transplantation NCG mice at 5 weeks ( n = 7). E Spleen size and percentage of hCD45 + leukemia cells in the spleen of the 1st transplantation recipient NCG mice at 5 weeks ( n = 7). F Kaplan‒Meier survival plot of the 2nd transplantation recipient NCG mice (E: T = 1:2, n = 8). G Percentage of human CD45 + leukemia cells in the PB and BM after the death of the 2nd transplantation recipient NCG mice at 5 weeks ( n = 5). H Spleen size and percentage of human CD45 + leukemia cells in the spleen of the 2nd transplantation recipient NCG mice after the death at 5 weeks ( n = 5). I Limiting dilution assays. The table (left) shows different numbers and treatment methods of transplanted leukemic cells with or without T cells and death numbers for each 2nd transplantation recipient NCG mouse. The table (middle) shows the LSC frequency in each transplantation recipient NCG mouse group. Limiting dilution assays of the 2nd transplantation showing the frequency of LSCs (right). BM: bone marrow; PB: peripheral blood; GFP: green fluorescent protein. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (t test). The error bars denote the means ± SDs

Techniques: In Vivo, Transplantation Assay

Loss of PSMB10 boosts chemotherapy-induced senescence in vitro and eradication of drug-resistant LSCs in vivo. A Statistical histogram of the mean fluorescence intensity of daunorubicin in the indicated lentivirus-transfected THP-1 and KG-1a cells. B-D Representative images of SA-β-gal staining ( B ) and the cell cycle distribution ( C-D ) in THP-1 and KG-1a cells transduced with the indicated lentiviruses under AraC (0.2 ug/ml) treatment. Scale bar, 50 µm. E Statistical histogram of the mean fluorescence intensity of daunorubicin in AML patient-derived BM CD34 + cells (FAB: M0/M1/M2) or BM mononuclear cells (FAB: M5) after transduction with the indicated siRNAs. F Experimental scheme for G-L . Created with figdraw.com. G Kaplan–Meier survival curves of C57BL/6J mice transplanted with either Psmb10 + / + or Psmb10 −/− MLL-AF9 leukemic cells, as well as those treated with chemotherapy drugs via intraperitoneal injection on day 14 post 1st BMT ( n = 8). H Percentages of GFP + leukemia cells in the BM after the death of 1st BMT recipient C57BL/6 J mice on day 21 ( n = 6). I Kaplan‒Meier survival curves for 2nd BMT recipient C57BL/6 J mice ( n = 8). J-K Percentages of GFP + leukemia cells in BM ( J ) and spleen ( K ), as well as spleen size after the death of 2nd BMT recipient C57BL/6 J mice ( n = 6). L Representative FCM images and statistical histograms illustrating the percentage of LSCs after the death of 2nd BMT recipient C57BL/6 J mice at 4 weeks ( n = 5–6). SA-β-Gal: senescence-associated β-galactosidase; siNC: small interfering RNA negative control; BM: bone marrow; AraC: Arabinoside Cytosine; DNR: Daunorubicin; ADM: Adriamycin; MA9: MLL-AF9; BMT: bone marrow transplantation. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 (t test). ns, not significant. The error bars denote the means ± SDs

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: Loss of PSMB10 boosts chemotherapy-induced senescence in vitro and eradication of drug-resistant LSCs in vivo. A Statistical histogram of the mean fluorescence intensity of daunorubicin in the indicated lentivirus-transfected THP-1 and KG-1a cells. B-D Representative images of SA-β-gal staining ( B ) and the cell cycle distribution ( C-D ) in THP-1 and KG-1a cells transduced with the indicated lentiviruses under AraC (0.2 ug/ml) treatment. Scale bar, 50 µm. E Statistical histogram of the mean fluorescence intensity of daunorubicin in AML patient-derived BM CD34 + cells (FAB: M0/M1/M2) or BM mononuclear cells (FAB: M5) after transduction with the indicated siRNAs. F Experimental scheme for G-L . Created with figdraw.com. G Kaplan–Meier survival curves of C57BL/6J mice transplanted with either Psmb10 + / + or Psmb10 −/− MLL-AF9 leukemic cells, as well as those treated with chemotherapy drugs via intraperitoneal injection on day 14 post 1st BMT ( n = 8). H Percentages of GFP + leukemia cells in the BM after the death of 1st BMT recipient C57BL/6 J mice on day 21 ( n = 6). I Kaplan‒Meier survival curves for 2nd BMT recipient C57BL/6 J mice ( n = 8). J-K Percentages of GFP + leukemia cells in BM ( J ) and spleen ( K ), as well as spleen size after the death of 2nd BMT recipient C57BL/6 J mice ( n = 6). L Representative FCM images and statistical histograms illustrating the percentage of LSCs after the death of 2nd BMT recipient C57BL/6 J mice at 4 weeks ( n = 5–6). SA-β-Gal: senescence-associated β-galactosidase; siNC: small interfering RNA negative control; BM: bone marrow; AraC: Arabinoside Cytosine; DNR: Daunorubicin; ADM: Adriamycin; MA9: MLL-AF9; BMT: bone marrow transplantation. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 (t test). ns, not significant. The error bars denote the means ± SDs

Techniques: In Vitro, In Vivo, Fluorescence, Transfection, Staining, Transduction, Derivative Assay, Injection, Small Interfering RNA, Negative Control, Transplantation Assay

$The increased PSMB10 impedes RPL6/RPS6-MDM2-P21-induced senescence initiation in AML cells. A Scattergram of upregulated pathways based on KEGG analysis of quantitative proteomics. B-C Changes in protein levels ( B ) and representative images of SA-β-Gal staining ( C ) in the indicated lentivirus-transfected THP-1 cells. Scale bar, 50 μm. D-G Immunoprecipitation assay between RPL6 or RPS6 and PSMB10 ( D ), RPS6 (top) or RPL6 (bottom) and MDM2 or PSMB10 ( E ), MDM2 and RPL6 or RPS6 or P21 ( F ), and MDM2 and P21 ( G ) in THP-1 cells. H shPSMB10-transfected THP-1 cells were treated with CHX for the indicated times, and RPS6 and RPL6 protein levels were detected via WB analysis. I Ubiquitination assay of (left) RPL6 and (right) RPS6 in shPSMB10- or shCTRL-transfected THP-1 cells. J-K Changes in the protein levels of RPL6, MDM2, and P21 ( J ), and representative images of SA-β-Gal staining ( K ) in shCTRL- and shRPL6-transduced THP-1 cells with shPSMB10. Scale bar, 50 μm. L Polysome profiling of shRPL6- or shCTRL-transduced THP-1 cells. M Polysome profiling coupled with qRT‒PCR analysis of shCTRL- and shRPL6-transduced THP-1 cells: MDM2 mRNA distribution in different ribosome fractions (left), and statistical histogram of MDM2 mRNA in the nonribosome portion and polysomes (right). N–O Changes in the protein levels of RPS6, MDM2, and P21 ( N ), and representative images of SA-β-Gal staining ( O ) in shCTRL- and shRPS6-transduced THP-1 cells with shPSMB10. Scale bar, 50 μm. P Statistical histogram of MDM2 translation initiation efficacy, defined as the quotient of reporter protein production (F-luc/R-luc). Q Immunoprecipitation assay between RPS6 and MDM2 in control shRNA- or RPL6 shRNA-transfected THP-1 cells transfected with shPSMB10. R Immunoprecipitation assay between RPL6 and MDM2 in control shRNA- or RPS6 shRNA-transfected THP-1 cells transfected with shPSMB10. OE: overexpression; SA-β-Gal: senescence-associated β-galactosidase; WT: wild-type; IP: immunoprecipitation; CHX: cycloheximide; Fract: fraction; IgG: Immunoglobulin G; NC: negative control; Ub: ubiquitination. **** p < 0.0001 (t test). ns, not significant. The error bars denote the means ± SDs$

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: The increased PSMB10 impedes RPL6/RPS6-MDM2-P21-induced senescence initiation in AML cells. A Scattergram of upregulated pathways based on KEGG analysis of quantitative proteomics. B-C Changes in protein levels ( B ) and representative images of SA-β-Gal staining ( C ) in the indicated lentivirus-transfected THP-1 cells. Scale bar, 50 μm. D-G Immunoprecipitation assay between RPL6 or RPS6 and PSMB10 ( D ), RPS6 (top) or RPL6 (bottom) and MDM2 or PSMB10 ( E ), MDM2 and RPL6 or RPS6 or P21 ( F ), and MDM2 and P21 ( G ) in THP-1 cells. H shPSMB10-transfected THP-1 cells were treated with CHX for the indicated times, and RPS6 and RPL6 protein levels were detected via WB analysis. I Ubiquitination assay of (left) RPL6 and (right) RPS6 in shPSMB10- or shCTRL-transfected THP-1 cells. J-K Changes in the protein levels of RPL6, MDM2, and P21 ( J ), and representative images of SA-β-Gal staining ( K ) in shCTRL- and shRPL6-transduced THP-1 cells with shPSMB10. Scale bar, 50 μm. L Polysome profiling of shRPL6- or shCTRL-transduced THP-1 cells. M Polysome profiling coupled with qRT‒PCR analysis of shCTRL- and shRPL6-transduced THP-1 cells: MDM2 mRNA distribution in different ribosome fractions (left), and statistical histogram of MDM2 mRNA in the nonribosome portion and polysomes (right). N–O Changes in the protein levels of RPS6, MDM2, and P21 ( N ), and representative images of SA-β-Gal staining ( O ) in shCTRL- and shRPS6-transduced THP-1 cells with shPSMB10. Scale bar, 50 μm. P Statistical histogram of MDM2 translation initiation efficacy, defined as the quotient of reporter protein production (F-luc/R-luc). Q Immunoprecipitation assay between RPS6 and MDM2 in control shRNA- or RPL6 shRNA-transfected THP-1 cells transfected with shPSMB10. R Immunoprecipitation assay between RPL6 and MDM2 in control shRNA- or RPS6 shRNA-transfected THP-1 cells transfected with shPSMB10. OE: overexpression; SA-β-Gal: senescence-associated β-galactosidase; WT: wild-type; IP: immunoprecipitation; CHX: cycloheximide; Fract: fraction; IgG: Immunoglobulin G; NC: negative control; Ub: ubiquitination. **** p < 0.0001 (t test). ns, not significant. The error bars denote the means ± SDs

Techniques: Quantitative Proteomics, Staining, Transfection, Immunoprecipitation, Ubiquitin Proteomics, Control, shRNA, Over Expression, Negative Control

Increased PSMB10 leads leukemia cell resistance to CTL-mediated killing through ubiquitinated degradation of MHC-I proteins. A-B MHC-I protein level changes ( A ), representative FCM images, and statistical histogram ( B ) of membrane MHC-I protein levels. C-D Representative FCM images for the percentage of Annexin V + apoptotic cells ( C ) and statistical histogram for the percentage of Annexin V + apoptotic cells ( D ) in the indicated lentivirus-transfected THP-1 cells after co-culture with activated human CD3 + T cells for 18 h at an effector-to-target (E: T) ratio of 1: 1. E Immunoprecipitation assay of MHC-I and PSMB10 in THP-1 cells. F shPSMB10 cells were treated with CHX at the indicated times, and MHC-I protein levels were detected via WB analysis. G Ubiquitination assays of MHC-I in lysates from shCTRL- or shPSMB10-transduced THP-1 cells. H Representative WB images of total MHC-I protein in shCTRL- or shβ2m-transduced THP-1 cells transfected with shPSMB10. I Representative FCM images and statistical histogram of membrane MHC-I protein levels. J Representative FCM images and statistical histogram of the percentage of Annexin V + apoptotic cells in shCTRL-, shPSMB10- and shβ2m-transduced THP-1 cells after co-culture with activated human CD3 + T cells for 18 h at an effector-to-target (E: T) ratio of 2: 1. MHC-I: major histocompatibility complex class I; CHX: cycloheximide; E: T: effector/target ratios; MFI: mean fluorescence intensity; OE: overexpression; IgG: Immunoglobulin G; Ub: ubiquitination. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 (t test). The error bars denote the means ± SDs

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: Increased PSMB10 leads leukemia cell resistance to CTL-mediated killing through ubiquitinated degradation of MHC-I proteins. A-B MHC-I protein level changes ( A ), representative FCM images, and statistical histogram ( B ) of membrane MHC-I protein levels. C-D Representative FCM images for the percentage of Annexin V + apoptotic cells ( C ) and statistical histogram for the percentage of Annexin V + apoptotic cells ( D ) in the indicated lentivirus-transfected THP-1 cells after co-culture with activated human CD3 + T cells for 18 h at an effector-to-target (E: T) ratio of 1: 1. E Immunoprecipitation assay of MHC-I and PSMB10 in THP-1 cells. F shPSMB10 cells were treated with CHX at the indicated times, and MHC-I protein levels were detected via WB analysis. G Ubiquitination assays of MHC-I in lysates from shCTRL- or shPSMB10-transduced THP-1 cells. H Representative WB images of total MHC-I protein in shCTRL- or shβ2m-transduced THP-1 cells transfected with shPSMB10. I Representative FCM images and statistical histogram of membrane MHC-I protein levels. J Representative FCM images and statistical histogram of the percentage of Annexin V + apoptotic cells in shCTRL-, shPSMB10- and shβ2m-transduced THP-1 cells after co-culture with activated human CD3 + T cells for 18 h at an effector-to-target (E: T) ratio of 2: 1. MHC-I: major histocompatibility complex class I; CHX: cycloheximide; E: T: effector/target ratios; MFI: mean fluorescence intensity; OE: overexpression; IgG: Immunoglobulin G; Ub: ubiquitination. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 (t test). The error bars denote the means ± SDs

Techniques: Membrane, Transfection, Co-Culture Assay, Immunoprecipitation, Ubiquitin Proteomics, Immunopeptidomics, Fluorescence, Over Expression

Psmb10 is dispensable for normal hematopoiesis. A Experimental scheme for B-D. Created with figdraw.com. B Numbers of WBC, platelet, HGB, and neutrophilic granulocyte percentage (Gran%) in PB of 16-week-old Psmb10 −/− or Psmb10 +/+ control C57BL/6 J mice ( n = 8). C-D Immunophenotypic quantification of HSC abundance (HSCs: Lin − Sca1 + cKit + CD48 − CD150 + ) ( C ), progenitor cells (Prog: Lin − Sca1 − c-Kit + ), CMPs (Lin − Sca1 − c-Kit + CD34 + CD16/32 − ), GMPs (Lin − Sca1 − c-Kit + CD34 + CD16/32 + ) and MEPs (Lin − Sca1 − c-Kit + CD34 − CD16/32 − ) ( D ) in the BM of 16-week-old Psmb10 −/− or Psmb10 + / + control C57BL/6 J mice ( n = 8). BMC: bone marrow cell; BMMNC: bone marrow mononuclear cell; CMP: common myeloid progenitors; HGB: Hemoglobin; HSC: hematopoietic stem cell; GMP: granulocyte–macrophage progenitors; gran: granulocytes; MEP: megakaryocyte-erythroid progenitors; PLT: platelet; WBC: white blood count; WT: wild-type. ns, not significant. The error bars denote the means ± SDs

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: Psmb10 is dispensable for normal hematopoiesis. A Experimental scheme for B-D. Created with figdraw.com. B Numbers of WBC, platelet, HGB, and neutrophilic granulocyte percentage (Gran%) in PB of 16-week-old Psmb10 −/− or Psmb10 +/+ control C57BL/6 J mice ( n = 8). C-D Immunophenotypic quantification of HSC abundance (HSCs: Lin − Sca1 + cKit + CD48 − CD150 + ) ( C ), progenitor cells (Prog: Lin − Sca1 − c-Kit + ), CMPs (Lin − Sca1 − c-Kit + CD34 + CD16/32 − ), GMPs (Lin − Sca1 − c-Kit + CD34 + CD16/32 + ) and MEPs (Lin − Sca1 − c-Kit + CD34 − CD16/32 − ) ( D ) in the BM of 16-week-old Psmb10 −/− or Psmb10 + / + control C57BL/6 J mice ( n = 8). BMC: bone marrow cell; BMMNC: bone marrow mononuclear cell; CMP: common myeloid progenitors; HGB: Hemoglobin; HSC: hematopoietic stem cell; GMP: granulocyte–macrophage progenitors; gran: granulocytes; MEP: megakaryocyte-erythroid progenitors; PLT: platelet; WBC: white blood count; WT: wild-type. ns, not significant. The error bars denote the means ± SDs

Techniques: Control

A proposed mechanism for the increased PSMB10 to maintain the stemness of drug-resistant leukemia cells. Created with figdraw.com. PSMB10 is significantly upregulated in chemotherapeutic drug-resistant LSCs, leading to the downregulation of both RPL6 and RPS6 proteins through ubiquitination-mediated degradation. Then the decreased RPL6 and RPS6 proteins, on the one hand, result in an increased MDM2 protein via the upregulation of translation activity, on the other hand, lead to a decreased RPs complex binding-induced conformational change of MDM2, which further promotes the MDM2-mediated ubiquitin-independent degradation of P21 Waf1 protein and resistance to senescence in AML cells. Besides, the increased PSMB10 also induces leukemia cell resistance to CTL-mediated killing by a direct binding and the ubiquitinated degradation of MHC-I proteins. AML: acute myeloid leukemia; Ub: ubiquitination; SASP: senescence-associated secretory phenotype; CTL: cytotoxic T lymphocyte; TCR: T-cell Receptor; β2m: β2-microglobulin; MHC-I: major histocompatibility complex class I

Journal: Journal of Experimental & Clinical Cancer Research : CR

doi: 10.1186/s13046-025-03420-9

Figure Lengend Snippet: A proposed mechanism for the increased PSMB10 to maintain the stemness of drug-resistant leukemia cells. Created with figdraw.com. PSMB10 is significantly upregulated in chemotherapeutic drug-resistant LSCs, leading to the downregulation of both RPL6 and RPS6 proteins through ubiquitination-mediated degradation. Then the decreased RPL6 and RPS6 proteins, on the one hand, result in an increased MDM2 protein via the upregulation of translation activity, on the other hand, lead to a decreased RPs complex binding-induced conformational change of MDM2, which further promotes the MDM2-mediated ubiquitin-independent degradation of P21 Waf1 protein and resistance to senescence in AML cells. Besides, the increased PSMB10 also induces leukemia cell resistance to CTL-mediated killing by a direct binding and the ubiquitinated degradation of MHC-I proteins. AML: acute myeloid leukemia; Ub: ubiquitination; SASP: senescence-associated secretory phenotype; CTL: cytotoxic T lymphocyte; TCR: T-cell Receptor; β2m: β2-microglobulin; MHC-I: major histocompatibility complex class I

Techniques: Ubiquitin Proteomics, Activity Assay, Binding Assay, Immunopeptidomics

Fig. 7. Models of 20Sc and 20Si proteasome assembly. (Upper), Model of 20Sc assembly

Journal: Journal of cell science

Article Title: PI31 is a positive regulator of 20S immunoproteasome assembly.

doi: 10.1242/jcs.263887

Figure Lengend Snippet: Fig. 7. Models of 20Sc and 20Si proteasome assembly. (Upper), Model of 20Sc assembly

Article Snippet: The following primary antibodies were used at 1:2,000 to 1:500 dilutions: Commercial antibodies 20Sc β2 subunit (Rabbit monoclonal IgG; Cell Signaling Technology #13207) 20Sc β2i subunit (Rabbit polyclonal; Cell Signaling Technology #78385) 20S 4 subunit (Mouse monoclonal IgG1, MCP34; Enzo BML-PW8120), 20S (Mouse monoclonal IgG1 (MCP231); Abcam ab22674), Jo ur na l o f C el l S ci en ce • A cc ep te d m an us cr ip t PI31 (Rabbit polyclonal; Abclonal BML-PW9710), PAC1 (Rabbit polyclonal; Cell Signaling Technology #13378), PAC3 (Mouse IgG2b; Proteintech #67466-1-Ig) POMP (Rabbit monoclonal IgG; Cell Signaling Technology #15141), Actin (mouse monoclonal C4; Sigma-Aldrich MAB1501), -Tubulin (Rabbit polyclonal; Cell signaling Technology #2146), Flag (mouse monoclonal; ThermoFisher Scientific #MA1-91878), Ubiquitin (Mouse monoclonal (FK2); Sigma-Aldrich #ST1200).

Techniques:

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 1 Immunoproteasome expression profile in muscle-invasive bladder cancer (MIBC). A Expression of immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in pan-tumor tissues and corresponding normal tissues derived from the TCGA dataset. Red boxes outline upregulation of PSMB8, PSMB9 and PSMB10 in bladder cancer tissues in contrast to normal tissues. Data are expressed as individual spots per subject with mean of the logarithm of transcripts per million. *p < 0.05, **p < 0.01, ***p < 0.001. B Expression of PSMB8, PSMB9 and PSMB10 in MIBC (n = 369) and normal tissues (n = 19) from the TCGA cohort. Data are expressed as individual spots per subject with mean ± SEM of the logarithm of transcripts per million. P-values are indicated in each graph. C Immunohistochemistry staining scores of PSMB8, PSMB9 and PSMB10 in MIBC (n = 67) and normal tissues (n = 18) derived from the CQUCH cohort. Data are expressed as individual spots per subject with mean ± SEM of each group. P-values are indicated in each graph. D Representative positive and negative immunohistochemistry stainings of PSMB8, PSMB9 and PSMB10 in MIBC and normal tissues derived from the CQUCH cohort. Scale bar: 40 μm. Positive stainings are divided into low and high expression by an average immunohistochemistry staining score

Article Snippet: Following incubation in phosphate-buffered saline containing 10% species-appropriate normal serum to block non-specific binding at room temperature for 1 h, sections were incubated in a humidified chamber with primary antibodies against PSMB8 (1:100; proteintech, Wuhan, China), PSMB9 (1:100; proteintech), PSMB10 (1:100; proteintech) and PD-L1 (1:100; proteintech) using isotype-matched IgGs as negative controls at 4 °C overnight.

Techniques: Expressing, Derivative Assay, Immunohistochemistry, Staining

Fig. 2 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the TCGA cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 2 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients in the TCGA cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Techniques: Expressing

Fig. 3 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients receiving immunotherapy. A Kaplan–Meier curve of overall survival for MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving immune checkpoint inhibitor treatment in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 3 Association of the expression of immunoproteasome subunits with survival prognosis in MIBC patients receiving immunotherapy. A Kaplan–Meier curve of overall survival for MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving immune checkpoint inhibitor treatment in the CQUCH cohort with high and low expression of PSMB8, PSMB9 and PSMB10

Techniques: Expressing

Fig. 4 Effect of immunotherapy (IMT) on survival prognosis in MIBC patients with different expression levels of immunoproteasome subunits. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with high expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with low expression of PSMB8, PSMB9 and PSMB10

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 4 Effect of immunotherapy (IMT) on survival prognosis in MIBC patients with different expression levels of immunoproteasome subunits. A Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with high expression of PSMB8, PSMB9 and PSMB10. B Kaplan–Meier curve of progression-free survival (upper panel) and overall survival (lower panel) for MIBC patients receiving IMT or not receiving (non-IMT) immune checkpoint inhibitor treatment in the CQUCH cohort with low expression of PSMB8, PSMB9 and PSMB10

Techniques: Expressing

Fig. 6 Association of immunoproteasome subunits with inflammatory factors in MIBC. Expression correlation heatmap of the association of IFN-γ and TNF with the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Correlation coefficient between each two molecules is written in each square. Color bar on the right side of each heatmap shows the correlation coefficient. Positive correlation is shown in red, negative and blue. C, D Kaplan–Meier curve of overall survival of MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of IFN-γ or TNF

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 6 Association of immunoproteasome subunits with inflammatory factors in MIBC. Expression correlation heatmap of the association of IFN-γ and TNF with the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Correlation coefficient between each two molecules is written in each square. Color bar on the right side of each heatmap shows the correlation coefficient. Positive correlation is shown in red, negative and blue. C, D Kaplan–Meier curve of overall survival of MIBC patients receiving immune checkpoint inhibitor treatment in the IMvigor210 cohort with high and low expression of IFN-γ or TNF

Techniques: Expressing

Fig. 7 Association of immunoproteasome subunits with tumor infiltrating immune cells in MIBC. Correlation lollipop charts of tumor infiltrating immune cells which were associated with the expression of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Lollipop size shows the correlation coefficient between each infiltrating immune cell type and each immunoproteasome subunit. P values were labeled on the right side of each chart. Values of P < 0.05 were considered statistically significant and marked in red

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 7 Association of immunoproteasome subunits with tumor infiltrating immune cells in MIBC. Correlation lollipop charts of tumor infiltrating immune cells which were associated with the expression of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 in MIBC of the TCGA cohort (A) and the IMvigor210 cohort (B). Lollipop size shows the correlation coefficient between each infiltrating immune cell type and each immunoproteasome subunit. P values were labeled on the right side of each chart. Values of P < 0.05 were considered statistically significant and marked in red

Techniques: Expressing, Labeling

Fig. 8 Association of immunoproteasome subunits with different immune-related functions and signaling in MIBC. A GO analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related functions in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown as the length of the column of each chart. B KEGG analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related signaling in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown by dot size. C GSEA analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with different immune cell functions in MIBC of the TCGA cohort

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Figure Lengend Snippet: Fig. 8 Association of immunoproteasome subunits with different immune-related functions and signaling in MIBC. A GO analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related functions in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown as the length of the column of each chart. B KEGG analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with immune-related signaling in MIBC of the TCGA cohort. Color bar shows the p-value on the right side of each chart. The number of related genes were shown by dot size. C GSEA analysis of the association of the immunoproteasome subunits PSMB8, PSMB9 and PSMB10 with different immune cell functions in MIBC of the TCGA cohort

Techniques:

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Techniques: Expressing, Derivative Assay, Immunohistochemistry, Staining

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Techniques: Expressing

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Techniques: Expressing

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Techniques: Expressing

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Techniques: Expressing

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Techniques: Expressing, Labeling

Journal: Journal of translational medicine

Article Title: Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

doi: 10.1186/s12967-025-06207-w

Techniques:

Review

Structured Review

Images

Similar Products

Image Search Results